🇺🇸 FDA
Pipeline program

9-ING-41

1902

Phase 1 small_molecule terminated

Quick answer

9-ING-41 for Refractory Cancer is a Phase 1 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ACTUATE THERAPEUTICS, INC.
Indication
Refractory Cancer
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials